Professor James Walters

2024

• Woolway, G. E. et al. 2024. Assessing the validity of a self-reported clinical diagnosis of schizophrenia. Schizophrenia 10(1), article number: 99. (10.1038/s41537-024-00526-5)
• Cardno, A. G. et al. 2024. Associations of psychotic symptom dimensions with clinical and developmental variables in twin and general clinical samples.. The British Journal of Psychiatry, pp. 1-8. (10.1192/bjp.2024.129)
• Koch, E. et al. 2024. How real-world data can facilitate the development of precision medicine treatment in psychiatry. Biological Psychiatry 96(7), pp. 543-551. (10.1016/j.biopsych.2024.01.001)
• Cameron, D. et al. 2024. Genetic implication of prenatal GABAergic and cholinergic neuron development in susceptibility to schizophrenia. Schizophrenia Bulletin Open 50(5), pp. 1171-1184. (10.1093/schbul/sbae083)
• Legge, S. E. et al. 2024. Genetic and phenotypic features of Schizophrenia in the UK Biobank. JAMA Psychiatry 81, pp. 681-690. (10.1001/jamapsychiatry.2024.0200)
• Trastulla, L. et al. 2024. Distinct genetic liability profiles define clinically relevant patient strata across common diseases. Nature Communications 15, article number: 5534. (10.1038/s41467-024-49338-2)
• Kendall, K., Duffin, D., Doherty, J., Irving, R., Procter, A. and Walters, J. 2024. The translation of psychiatric genetics findings to the clinic. Schizophrenia Research 267, pp. 470-472. (10.1016/j.schres.2023.10.024)
• Caseras, X. et al. 2024. Common risk alleles for schizophrenia within the major histocompatibility complex predict white matter microstructure. Translational Psychiatry 14, article number: 194. (10.1038/s41398-024-02910-2)
• Kappel, D. et al. 2024. Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia. European Neuropsychopharmacology 80, pp. 47-54. (10.1016/j.euroneuro.2023.12.007)
• Casetta, C. et al. 2024. CLEAR – clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings. BMC Psychiatry 24(1), article number: 122. (10.1186/s12888-023-05397-1)
• O'Connell, K. et al. 2024. Genomics yields biological and phenotypic insights into bipolar disorder. Biological Psychiatry

2023

• Davies, H. L. et al. 2023. The network structure of mania symptoms differs between people with and without binge eating. Bipolar Disorders 25(7), pp. 592-607. (10.1111/bdi.13355)
• Lee, S. C., DelPozo-Banos, M., Lloyd, K., Jones, I., Walters, J. and John, A. 2023. Trends in socioeconomic inequalities in incidence of severe mental illness – A population-based linkage study using primary and secondary care routinely collected data between 2000 and 2017. Schizophrenia Research 260, pp. 113-122. (10.1016/j.schres.2023.08.014)
• Griffiths, K. et al. 2023. Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia. Schizophrenia Research 260, pp. 152-159. (10.1016/j.schres.2023.08.020)
• Lock, S. K. et al. 2023. Mediation and longitudinal analysis to interpret the association between clozapine pharmacokinetics, pharmacogenomics, and absolute neutrophil count. Schizophrenia 9, article number: 74. (10.1038/s41537-023-00404-6)
• Palmer, E. R. et al. 2023. Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial. Trials 24(1), article number: 646. (10.1186/s13063-023-07499-3)
• Doherty, A., O'Donovan, M., Hamshere, M., Jones, I., Owen, M. and Walters, J. 2023. Genome-wide association study meta-analysis of suicide attempt identifies twelve genome-wide significant loci and implicates genetic risks for specific health factors. The American Journal of Psychiatry 180(10), pp. 723-738. (10.1176/appi.ajp.21121266)
• Owen, M., Legge, S., Rees, E., Walters, J. and O'Donovan, M. 2023. Genomic findings in schizophrenia and their implications. Molecular Psychiatry 28, pp. 3638-3647. (10.1038/s41380-023-02293-8)
• Lynham, A., Jones, I. and Walters, J. 2023. Cardiff online cognitive assessment in a national sample: cross-sectional web-based study. Journal of Medical Internet Research 25, article number: e46675. (10.2196/46675)
• Ollà, I. et al. 2023. Pathogenic mis-splicing of CPEB4 in schizophrenia. Biological Psychiatry 94(4), pp. 341-351. (10.1016/j.biopsych.2023.03.010)
• Maury, E. A. et al. 2023. Schizophrenia-associated somatic copy-number variants from 12,834 cases reveal recurrent NRXN1 and ABCB11 disruptions. Cell Genomics 3(8), article number: 100356. (10.1016/j.xgen.2023.100356)
• Fenn-Moltu, S. et al. 2023. The association between peripheral inflammation, brain glutamate and antipsychotic response in Schizophrenia: Data from the STRATA collaboration. Brain, Behavior, and Immunity 111, pp. 343-351. (10.1016/j.bbi.2023.05.005)
• Bright, S. J. et al. 2023. Sociodemographic, mental health, and physical health factors associated with participation within re-contactable mental health cohorts: an investigation of the GLAD Study. BMC Psychiatry 23, article number: 542. (10.1186/s12888-023-04890-x)
• Allardyce, J. et al. 2023. Specificity of polygenic signatures across symptom dimensions in bipolar disorder: an analysis of UK Bipolar Disorder Research Network data. The Lancet Psychiatry 10(8), pp. 623-631. (10.1016/S2215-0366(23)00186-4)
• Millgate, E. et al. 2023. Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study. Schizophrenia Research 255, pp. 173-181. (10.1016/j.schres.2023.03.020)
• Johnson, E. C. et al. 2023. Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder. Psychological Medicine 53(4), pp. 1196-1204. (10.1017/S003329172100266X)
• Lynham, A. J. et al. 2023. DRAGON-Data: A platform and protocol for integrating genomic and phenotypic data across large psychiatric cohorts. BJPsych Open 9(2), article number: e32. (10.1192/bjo.2022.636)
• Pardinas, A. F. et al. 2023. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. The Lancet Psychiatry 10(3), pp. 209-219. (10.1016/S2215-0366(23)00002-0)
• Rammos, A., Kirov, G., Hubbard, L., Walters, J., Holmans, P., Owen, M. and Rees, E. 2023. Family-based analysis of the contribution of rare and common genetic variants to school performance in schizophrenia. Molecular Psychiatry 28, pp. 2081-2087. (10.1038/s41380-023-02013-2)
• Liu, D. et al. 2023. Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations. Nature Genetics 55, pp. 369-376. (10.1038/s41588-023-01305-1)
• Davies, M. R. et al. 2023. Factors associated with anxiety disorder comorbidity. Journal of Affective Disorders 323, pp. 280-291. (10.1016/j.jad.2022.11.051)
• Kappel, D. B. et al. 2023. Genomic stratification of clozapine prescription patterns using schizophrenia polygenic scores. Biological Psychiatry 93, pp. 149-156. (10.1016/j.biopsych.2022.07.014)

2022

• Pistis, G. et al. 2022. Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis. Molecular Psychiatry 27, pp. 5135-5143. (10.1038/s41380-022-01779-1)
• Smart, S. E. et al. 2022. Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium. Schizophrenia Research 250, pp. 1-9. (10.1016/j.schres.2022.09.009)
• Rayner, C. et al. 2022. Patient characteristics associated with retrospectively self-reported treatment outcomes following psychological therapy for anxiety or depressive disorders - a cohort of GLAD study participants. BMC Psychiatry 22(1), article number: 719. (10.1186/s12888-022-04275-6)
• Woolway, G. et al. 2022. Schizophrenia polygenic risk and experiences of childhood adversity: a systematic review and meta-analysis. Schizophrenia Bulletin 48(5), pp. 967-980. (10.1093/schbul/sbac049)
• Bracher-Smith, M. et al. 2022. Machine learning for prediction of schizophrenia using genetic and demographic factors in the UK Biobank. Schizophrenia Research 246, pp. 156-164. (10.1016/j.schres.2022.06.006)
• Richards, A. et al. 2022. Genetic liabilities differentiating bipolar disorder, schizophrenia and major depression and phenotypic heterogeneity in bipolar disorder. JAMA Psychiatry 79(10), pp. 1032-1039. (10.1001/jamapsychiatry.2022.2594)
• Creeth, H. D. J. et al. 2022. Ultrarare coding variants and cognitive function in schizophrenia. JAMA Psychiatry 79(10), pp. 963-970. (10.1001/jamapsychiatry.2022.2289)
• D’Ambrosio, E. et al. 2022. A polygenic score indexing a DRD2 -related co-expression network is associated with striatal dopamine function. Scientific Reports 12(1), article number: 12610. (10.1038/s41598-022-16442-6)
• Griffiths, K. et al. 2022. Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study. Schizophrenia 8(1), article number: 60. (10.1038/s41537-022-00265-5)
• Palmer, D. et al. 2022. Exome sequencing in bipolar disorder reveals AKAP11 as a risk gene shared with schizophrenia. Nature Genetics (10.1038/s41588-022-01034-x)
• Chambers, T. et al. 2022. Genetic common variants associated with cerebellar volume and their overlap with mental disorders: a study on 33,265 individuals from the UK-Biobank. Molecular Psychiatry 27, pp. 2282-2290. (10.1038/s41380-022-01443-8)
• Trubetskoy, V. et al. 2022. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. Nature 604, pp. 502-508. (10.1038/s41586-022-04434-5)
• Singh, T., Schizophrenia Exome Meta-Analysis (SCHEMA) Consortium, ., Kirov, G., Rees, E., Walters, J., Owen, M. and O'Donovan, M. 2022. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature 604, pp. 509-516. (10.1038/s41586-022-04556-w)
• Okhuijsen-Pfeifer, C. et al. 2022. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders. Translational Psychiatry 12, article number: 145. (10.1038/s41398-022-01884-3)
• Alamian, G. et al. 2022. Altered brain criticality in schizophrenia: new insights from magnetoencephalography. Frontiers in Neural Circuits 16, article number: 630621. (10.3389/fncir.2022.630621)
• Lynham, A. J., Jones, I. R. and Walters, J. T. R. 2022. Web-based cognitive testing in psychiatric research: validation and usability study. Journal of Medical Internet Research 24(2), article number: e28233. (10.2196/28233)
• Mullins, N. et al. 2022. Dissecting the shared genetic architecture of suicide attempt, psychiatric disorders and known risk factors. Biological Psychiatry 91(3), pp. 313-327. (10.1016/j.biopsych.2021.05.029)
• Warne, N. et al. 2022. Collecting genetic samples and linked mental health data from adolescents in schools: protocol co-production and a mixed-methods pilot of feasibility and acceptability. BMJ Open 12(2), article number: e049283. (10.1136/bmjopen-2021-049283)
• Jones, H. J. et al. 2022. Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence. Psychological Medicine 52(1), pp. 132-139. (10.1017/S0033291720001798)
• Lynham, A. J., Cleaver, S. L., Jones, I. R. and Walters, J. T. R. 2022. A meta-analysis comparing cognitive function across the mood/psychosis diagnostic spectrum. Psychological Medicine 52(2), pp. 323-331. (10.1017/S0033291720002020)
• Vassos, E. et al. 2022. Lack of support for the genes by early environment interaction hypothesis in the pathogenesis of schizophrenia. Schizophrenia Bulletin 48(1), pp. 20-26. (10.1093/schbul/sbab052)
• Davies, M. R. et al. 2022. Comparison of symptom-based versus self-reported diagnostic measures of anxiety and depression disorders in the GLAD and COPING cohorts. Journal of Anxiety Disorders 85, article number: 102491. (10.1016/j.janxdis.2021.102491)
• Pardinas, A. et al. 2022. Interaction testing and polygenic risk scoring to estimate the contribution of common genetic variants to treatment resistance in schizophrenia. JAMA Psychiatry 79(3), pp. 260-269. (10.1001/jamapsychiatry.2021.3799)

2021

• Pardinas, A. F., Owen, M. J. and Walters, J. T. 2021. Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron 109(24), pp. 3914-3929. (10.1016/j.neuron.2021.09.011)
• Millgate, E. et al. 2021. A cross sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study. BMJ Open 11, article number: e054160. (10.1136/bmjopen-2021-054160)
• Thompson, K. N. et al. 2021. Age and sex-related variability in the presentation of generalized anxiety and depression symptoms. Depression and Anxiety 38(10), pp. 1054-1065. (10.1002/da.23213)
• Jia, X. et al. 2021. Investigating rare pathogenic/likely pathogenic exonic variation in bipolar disorder. Molecular Psychiatry 26, pp. 5239-5250. (10.1038/s41380-020-01006-9)
• Dennison, C. et al. 2021. Risk factors, clinical features, and polygenic risk scores in schizophrenia and schizoaffective disorder depressive-type. Schizophrenia Bulletin 47(5), pp. 1375-1384. (10.1093/schbul/sbab036)
• Clifton, N. E. et al. 2021. Developmental profile of psychiatric risk associated with voltage-gated cation channel activity. Biological Psychiatry 90(6) (10.1016/j.biopsych.2021.03.009)
• Rees, E. et al. 2021. Schizophrenia, autism spectrum disorders and developmental disorders share specific disruptive coding mutations. Nature Communications 12, article number: 5353. (10.1038/s41467-021-25532-4)
• Martin, J. et al. 2021. Examining sex differences in neurodevelopmental and psychiatric genetic risk in anxiety and depression. PLoS ONE 16(9), article number: e0248254. (10.1371/journal.pone.0248254)
• Cleynen, I. et al. 2021. Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry, pp. 4496-4510. (10.1038/s41380-020-0654-3)
• Legge, S. et al. 2021. Associations between schizophrenia polygenic liability, symptom dimensions, and cognitive ability in schizophrenia. JAMA Psychiatry 78(10), pp. 1143-1151. (10.1001/jamapsychiatry.2021.1961)
• Greene, M. C. et al. 2021. The epidemiology of psychiatric disorders in Africa: a scoping review. The Lancet Psychiatry 8(8), pp. 717-731. (10.1016/S2215-0366(21)00009-2)
• Clifton, N. E. et al. 2021. Genetic association of FMRP targets with psychiatric disorders. Molecular Psychiatry 26, pp. 2977-2990. (10.1038/s41380-020-00912-2)
• Hubbard, L. et al. 2021. Rare copy number variations are associated with poorer cognition in schizophrenia. Biological Psychiatry 90(1), pp. 28-34. (10.1016/j.biopsych.2020.11.025)
• Byrne, E. et al. 2021. Conditional GWAS analysis to identify disorder-specific SNPs for psychiatric disorders. Molecular Psychiatry 26, pp. 2070-2081. (10.1038/s41380-020-0705-9)
• Hall, L. S. et al. 2021. Cis-effects on gene expression in the human prenatal brain associated with genetic risk for neuropsychiatric disorders. Molecular Psychiatry 26, pp. 2082-2088. (10.1038/s41380-020-0743-3)
• Mullins, N. et al. 2021. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics 53, pp. 817-829. (10.1038/s41588-021-00857-4)
• Peterson, R. E. et al. 2021. Genome-wide analyses of smoking behaviors in schizophrenia: findings from the Psychiatric Genomics Consortium. Journal of Psychiatric Research 137, pp. 215-225. (10.1016/j.jpsychires.2021.02.027)
• Enache, D. et al. 2021. Peripheral immune markers and antipsychotic non-response in psychosis. Schizophrenia Research 230, pp. 1-8. (10.1016/j.schres.2020.12.020)
• Willcocks, I. et al. 2021. Clozapine metabolism is associated with absolute neutrophil count in individuals with treatment-resistant schizophrenia. Frontiers in Pharmacology 12, article number: 658734. (10.3389/fphar.2021.658734)
• Konte, B. et al. 2021. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Translational Psychiatry 11, article number: 214. (10.1038/s41398-021-01322-w)
• Egerton, A. et al. 2021. Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA). Schizophrenia Bulletin 47(2), pp. 505-516. (10.1093/schbul/sbaa128)
• Dennison, C. A. et al. 2021. Association of genetic liability for psychiatric disorders with accelerometer-assessed physical activity in the UK Biobank. PLoS ONE 16(3), article number: e0249189. (10.1371/journal.pone.0249189)
• Gascoyne, L. E. et al. 2021. Motor-related oscillatory activity in schizophrenia according to phase of illness and clinical symptom severity. NeuroImage: Clinical 29, article number: 102524. (10.1016/j.nicl.2020.102524)
• Chauquet, S., Zhu, Z., O'Donovan, M., Walters, J., Wray, N. and Shah, S. 2021. Investigating the potential effects of antihypertensive medication on psychiatric disorders: a mendelian randomisation study. JAMA Psychiatry 78(6), pp. 623-631. (10.1001/jamapsychiatry.2021.0005)

2020

• Kendall, K. M. et al. 2020. Impact of schizophrenia genetic liability on the association between schizophrenia and physical illness: a data linkage study. BJPsych Open 6(6), article number: e139. (10.1192/bjo.2020.42)
• Alamian, G., Pascarella, A., Tarek, L., Knight, L., Walters, J., Singh, K. D. and Jerbi, K. 2020. Patient, interrupted: MEG oscillation dynamics reveal temporal dysconnectivity in schizophrenia. NeuroImage: Clinical 28, article number: 102485. (10.1016/j.nicl.2020.102485)
• Legge, S. E. et al. 2020. The Duffy-null genotype and risk of infection. Human Molecular Genetics 29(20), pp. 3341-3349. (10.1093/hmg/ddaa208)
• Jones, H. J. et al. 2020. A Mendelian randomization study of the causal association between anxiety phenotypes and schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 183(6), pp. 360-369. (10.1002/ajmg.b.32808)
• Lee, S. C. et al. 2020. Area deprivation, urbanicity, severe mental illness and social drift — a population-based linkage study using routinely collected primary and secondary care data. Schizophrenia Research 220, pp. 130-140. (10.1016/j.schres.2020.03.044)
• Legge, S. et al. 2020. Clinical indicators of treatment-resistant psychosis. British Journal of Psychiatry 216(5), pp. 259-266. (10.1192/bjp.2019.120)
• Foley, C. et al. 2020. Identifying schizophrenia patients who carry pathogenic genetic copy number variants using standard clinical assessment: retrospective cohort study. British Journal of Psychiatry 216(5), pp. 275-279. (10.1192/bjp.2019.262)
• Richards, A. et al. 2020. The relationship between polygenic risk scores and cognition in schizophrenia. Schizophrenia Bulletin 46(2), pp. -. (10.1093/schbul/sbz061)
• Dennison, C. A., Legge, S. E., Pardinas, A. F. and Walters, J. T. 2020. Genome-wide association studies in schizophrenia: Recent advances, challenges and future perspective. Schizophrenia Research 217, pp. 4-12. (10.1016/j.schres.2019.10.048)
• Rees, E. et al. 2020. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia. Nature Neuroscience 23(2), pp. 179-184. (10.1038/s41593-019-0565-2)
• Hall, L. S. et al. 2020. A transcriptome-wide association study implicates specific pre- and post-synaptic abnormalities in schizophrenia. Human Molecular Genetics 29(1), pp. 159-167. (10.1093/hmg/ddz253)

2019

• Legge, S. E. et al. 2019. Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits. JAMA Psychiatry 76(12), pp. 1256-1265. (10.1001/jamapsychiatry.2019.2508)
• Davies, M. R. et al. 2019. The Genetic Links to Anxiety and Depression (GLAD) study: online recruitment into the largest recontactable study of depression and anxiety. Behaviour Research and Therapy 123, article number: 103503. (10.1016/j.brat.2019.103503)
• Lee, P. H. et al. 2019. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 179(7), pp. 1469-1482.e11. (10.1016/j.cell.2019.11.020)
• Escott-Price, V. et al. 2019. Polygenic risk for schizophrenia and season of birth within the UK Biobank cohort. Psychological Medicine 49(15), pp. 2499-2504. (10.1017/S0033291718000454)
• D'Ambrosio, E. et al. 2019. The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study. Psychiatry Research: Neuroimaging 291, pp. 34-41. (10.1016/j.pscychresns.2019.07.005)
• Mulllins, N. et al. 2019. GWAS of suicide attempt in psychiatric disorders identifies association with major depression polygenic risk scores. American Journal of Psychiatry 176(8), pp. 651-660. (10.1176/appi.ajp.2019.18080957)
• Escott-Price, V., Pardinas, A. F., Santiago, E., Walters, J., Kirov, G., Owen, M. J. and O'Donovan, M. C. 2019. The relationship between common variant schizophrenia liability and number of offspring in the UK Biobank. American Journal of Psychiatry 176(8), pp. 661-666. (10.1176/appi.ajp.2018.18020140)
• Shaw, A. D. et al. 2019. Oscillatory, computational and behavioural evidence for impaired GABAergic inhibition in schizophrenia. Schizophrenia Bulletin 46(2), pp. 345-353. (10.1093/schbul/sbz066)
• Pardinas, A. F. et al. 2019. Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism. American Journal of Psychiatry 176(6), pp. 477-486. (10.1176/appi.ajp.2019.18050589)
• Pettersson, E. et al. 2019. Genetic influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings, and genetic data of 333 748 cases and controls. Psychological Medicine 49(7), pp. 1166-1173. (10.1017/S0033291718002039)
• Kendall, K. M. et al. 2019. Cognitive performance and functional outcomes of carriers of pathogenic copy number variants: analysis of the UK Biobank. British Journal of Psychiatry 214(5), pp. 297-304. (10.1192/bjp.2018.301)
• Huckins, L. M. et al. 2019. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nature Genetics 51, pp. 659-674. (10.1038/s41588-019-0364-4)
• Kendall, K. M. et al. 2019. Association of rare copy number variants with risk of depression. JAMA Psychiatry 76(8), pp. 818-825. (10.1001/jamapsychiatry.2019.0566)
• Gorman, K. M. et al. 2019. Bi-allelic loss-of-function CACNA1B mutations in progressive epilepsy-dyskinesia. American Journal of Human Genetics 104(5), pp. 948-956. (10.1016/j.ajhg.2019.03.005)
• Rees, E. et al. 2019. Targeted sequencing of 10,198 samples confirms abnormalities in neuronal activity and implicates voltage-gated sodium channels in schizophrenia pathogenesis. Biological Psychiatry 85(7), pp. 554-562. (10.1016/j.biopsych.2018.08.022)
• Harold, D. et al. 2019. Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 180(3), pp. 223-231. (10.1002/ajmg.b.32716)
• Legge, S. E. et al. 2019. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Molecular Psychiatry 24, pp. 328-337. (10.1038/s41380-018-0335-7)
• Legge, S. E. and Walters, J. T. 2019. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. Pharmacogenomics 20(4), pp. 279-290. (10.2217/pgs-2018-0188)
• Crawford, K. et al. 2019. Medical consequences of pathogenic CNVs in adults: Analysis of the UK Biobank. Journal of Medical Genetics 56, pp. 131-138. (10.1136/jmedgenet-2018-105477)
• Clifton, N. E. et al. 2019. Dynamic expression of genes associated with schizophrenia and bipolar disorder across development. Translational Psychiatry 9, article number: 74. (10.1038/s41398-019-0405-x)
• Escott-Price, V., Bracher-Smith, M., Menzies, G., Walters, J., Kirov, G., Owen, M. J. and O'Donovan, M. C. 2019. Genetic liability to schizophrenia is negatively associated with educational attainment in UK Biobank. Journal of Molecular Psychiatry, pp. -. (10.1038/s41380-018-0328-6)
• Vivian-Griffiths, T. et al. 2019. Predictive modeling of schizophrenia from genomic data: Comparison of polygenic risk score with kernel support vector machines approach. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 180(1), pp. 80-85. (10.1002/ajmg.b.32705)

2018

• Li, M. et al. 2018. Integrative functional genomic analysis of human brain development and neuropsychiatric risks. Science 362(6420), article number: eaat7615. (10.1126/science.aat7615)
• Dahoun, T. et al. 2018. The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study. Human Molecular Genetics 27(20), pp. 3498-3506. (10.1093/hmg/ddy242)
• John, A. et al. 2018. Premature mortality among people with severe mental illness - new evidence from linked primary care data. Schizophrenia Research 199, pp. 154-162. (10.1016/j.schres.2018.04.009)
• Jones, H. J. et al. 2018. Investigating the genetic architecture of general and specific psychopathology in adolescence. Translational Psychiatry 8(1), article number: 145. (10.1038/s41398-018-0204-9)
• Skene, N. G. et al. 2018. Genetic identification of brain cell types underlying schizophrenia. Nature Genetics 50, pp. 825-833. (10.1038/s41588-018-0129-5)
• Anttila, V. et al. 2018. Analysis of shared heritability in common disorders of the brain. Science 360(6395), article number: eaap8757. (10.1126/science.aap8757)
• Ruderfer, D. M. et al. 2018. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell 173(7), pp. 1705-1715.e16. (10.1016/j.cell.2018.05.046)
• Leonenko, G. et al. 2018. A data-driven investigation of relationships between bipolar psychotic symptoms and schizophrenia genome-wide significant genetic loci. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 177(4), pp. 468-475. (10.1002/ajmg.b.32635)
• Blokland, G. A. et al. 2018. The genetics of endophenotypes of neurofunction to understand schizophrenia (GENUS) consortium: a collaborative cognitive and neuroimaging genetics project. Schizophrenia Research 195, pp. 306-317. (10.1016/j.schres.2017.09.024)
• Reddaway, J., Doherty, J. L., Lancaster, T., Linden, D., Walters, J. T. and Hall, J. 2018. Genomic and imaging biomarkers in schizophrenia. In: Current Topics in Behavioral Neurosciences. Berlin and Heidelberg: Springer, pp. 325-352., (10.1007/7854_2018_52)
• Lynham, A. et al. 2018. Examining cognition across the bipolar / schizophrenia diagnostic spectrum. Journal of Psychiatry and Neuroscience 43(3), article number: 170076. (10.1503/jpn.170076)
• Pardinas, A. F. et al. 2018. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nature Genetics 50, pp. 381-389. (10.1038/s41588-018-0059-2)
• Ellis, N. C., Quraishy, M., Hoskins, M., Walters, J., Riley, S. and Forty, L. 2018. Medical student attitudes to mental health and psychiatry: the use of a patient-experience short film. The British Student Doctor Journal 2(1), pp. 3-10. (10.18573/bsdj.37)
• Allardyce, J. et al. 2018. Association between schizophrenia-related polygenic liability and the occurrence and level of mood-incongruent psychotic symptoms in bipolar disorder. JAMA Psychiatry 75(1), pp. 28-35. (10.1001/jamapsychiatry.2017.3485)

2017

• Cosgrove, D. et al. 2017. Cognitive characterization of schizophrenia risk variants involved in synaptic transmission: evidence of CACNA1C's role in working memory. Neuropsychopharmacology 42, pp. 2612-2622. (10.1038/npp.2017.123)
• Leonenko, G. et al. 2017. Mutation intolerant genes and targets of FMRP are enriched for nonsynonymous alleles in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 174(7), pp. 724-731. (10.1002/ajmg.b.32560)
• Legge, S. E. et al. 2017. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular Psychiatry 22, pp. 1502-1508. (10.1038/mp.2016.97)
• Chawner, S., Doherty, J. L., Moss, H., Niarchou, M., Walters, J., Owen, M. J. and Van Den Bree, M. B. 2017. Childhood cognitive development in 22q11.2 deletion syndrome: case–control study. British Journal of Psychiatry 211(4), pp. 223-230. (10.1192/bjp.bp.116.195651)
• Singh, T. et al. 2017. The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nature Genetics 49, pp. 1167-1173. (10.1038/ng.3903)
• Kendall, K. M. et al. 2017. Cognitive performance among carriers of pathogenic copy number variants: analysis of 152,000 UK Biobank subjects. Biological Psychiatry 82(2), pp. P103-110. (10.1016/j.biopsych.2016.08.014)
• Allardyce, J. et al. 2017. Psychosis and the level of mood incongruence in Bipolar Disorder are related to genetic liability for Schizophrenia. [Online]. bioRxiv. Available at: http://dx.doi.org/10.1101/160119
• Blokland, G. A. M. et al. 2017. Heritability of neuropsychological measures in Schizophrenia and non-psychiatric populations: a systematic review and meta-analysis. Schizophrenia Bulletin 43(4), pp. 788-800. (10.1093/schbul/sbw146)
• Hendricks, A. E. et al. 2017. Rare variant analysis of human and rodent obesity genes in individuals with severe childhood obesity. Scientific Reports 7, article number: 4394. (10.1038/s41598-017-03054-8)
• Hassoulas, A., Forty, E., Hoskins, M., Walters, J. and Riley, S. 2017. A case-based medical curriculum for the 21st century: The use of innovative approaches in designing and developing a case on mental health. Medical Teacher 39(5), pp. 505-511. (10.1080/0142159X.2017.1296564)
• Howes, O. D. et al. 2017. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. The American Journal of Psychiatry 174(3), pp. 216-229. (10.1176/appi.ajp.2016.16050503)
• Clifton, N. E. et al. 2017. Schizophrenia copy number variants and associative learning. Molecular Psychiatry 22(2), pp. 178-182. (10.1038/mp.2016.227)
• Marshall, C. R. et al. 2017. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics 49, pp. 27-35. (10.1038/ng.3725)

2016

• Whitton, L. et al. 2016. Cognitive analysis of schizophrenia risk genes that function as epigenetic regulators of gene expression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 171(8), pp. 1170-1179. (10.1002/ajmg.b.32503)
• Rees, E. et al. 2016. Analysis of intellectual disability copy number variants for association with schizophrenia. JAMA Psychiatry 73(9), pp. 963-969. (10.1001/jamapsychiatry.2016.1831)
• Tansey, K. E. et al. 2016. Common alleles contribute to schizophrenia in CNV carriers. Molecular Psychiatry 21, pp. 1085-1089. (10.1038/mp.2015.143)
• Pardinas, A. et al. 2016. Common schizophrenia alleles are enriched in mutation-intolerant genes and maintained by background selection. [Online]. bioRxiv. (10.1101/068593) Available at: http://dx.doi.org/10.1101/068593
• Legge, S. et al. 2016. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophrenia Research 174, pp. 113-119. (10.1016/j.schres.2016.05.002)
• Han, J. et al. 2016. Gender differences in CNV burden do not confound schizophrenia CNV associations. Scientific Reports 6, article number: 25986. (10.1038/srep25986)
• Isles, A. R. et al. 2016. Parental origin of interstitial duplications at 15q11.2-q13.3 in schizophrenia and neurodevelopmental disorders. PLoS Genetics 12(5), article number: e1005993. (10.1371/journal.pgen.1005993)
• Walters, J. T. R. and Owen, M. J. 2016. Genome-wide significant associations for cannabis dependence severity. JAMA Psychiatry 73(5), pp. 443-444. (10.1001/jamapsychiatry.2016.0046)
• Thompson, J. V. et al. 2016. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. Journal of Psychopharmacology 30(5), pp. 436-443. (10.1177/0269881116632376)
• Singh, T. et al. 2016. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nature Neuroscience 19(4), pp. 571-577. (10.1038/nn.4267)
• Carroll, L. S. et al. 2016. Mutation screening of SCN2A in schizophrenia and identification of a novel loss-of-function mutation. Psychiatric Genetics 26(2), pp. 60-65. (10.1097/YPG.0000000000000110)
• Franke, B. et al. 2016. Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nature Neuroscience 19(3), pp. 420-431. (10.1038/nn.4228)
• Singh, T. et al. 2016. Rare loss-of-function variants in KMT2F are associated with schizophrenia and developmental disorders. Nature Neuroscience 19, pp. 571-577. (10.1101/036384)
• Richards, A. et al. 2016. Exome arrays capture polygenic rare variant contributions to schizophrenia. Human Molecular Genetics 25(5), pp. 1001-1007. (10.1093/hmg/ddv620)
• Jones, H. J. et al. 2016. Phenotypic manifestation of genetic risk for schizophrenia during adolescence in the general population. JAMA Psychiatry 73(3), pp. 221-228. (10.1001/jamapsychiatry.2015.3058)
• Hubbard, L. et al. 2016. Evidence of common genetic overlap between schizophrenia and cognition. Schizophrenia Bulletin 42(3), pp. 832-842. (10.1093/schbul/sbv168)

2015

• Tansey, K. E. et al. 2015. Common alleles contribute to schizophrenia in CNV carriers [Erratum]. Molecular Psychiatry 21, article number: 1153. (10.1038/mp.2015.170)
• Walter, K. et al. 2015. The UK10K project identifies rare variants in health and disease. Nature 526, pp. 82-90. (10.1038/nature14962)
• Huang, J. et al. 2015. Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel. Nature Communications 6, article number: 8111. (10.1038/ncomms9111)
• Lloyd, K. et al. 2015. A national population-based e-cohort of people with psychosis (PsyCymru) linking prospectively ascertained phenotypically rich and genetic data to routinely collected records: Overview, recruitment and linkage. Schizophrenia Research 166(1-3), pp. 131-6. (10.1016/j.schres.2015.05.036)
• Loohuis, L. M. O. et al. 2015. Genome-wide burden of deleterious coding variants increased in schizophrenia. Nature Communications 6, article number: 7501. (10.1038/ncomms8501)
• Pocklington, A. et al. 2015. Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia. Neuron 86(5), pp. 1203-1214. (10.1016/j.neuron.2015.04.022)
• Kirov, G., Rees, E. and Walters, J. T. R. 2015. What a psychiatrist needs to know about copy number variants. BJPscyh Advances 21(3), pp. 157-163. (10.1192/apt.bp.113.012039)
• Collier, D. et al. 2015. How can pharmacogenomics biomarkers be translated into patient benefit [Conference Abstract]. European Psychiatry 30(Suppl1), pp. 94-94. (10.1016/S0924-9338(15)30078-X)
• Vivian-Griffiths, T. et al. 2015. Utilising machine-learning algorithms to uncover complex genetic interactions in schizophrenia [Conference Abstract]. Human Heredity 79(1), pp. 48-48., article number: A46. (10.1159/000381109)
• Taylor, P. N. et al. 2015. Whole-genome sequence-based analysis of thyroid function. Nature Communications 6, article number: 5681. (10.1038/ncomms6681)
• Walters, J. T. R. 2015. Treatment resistant schizophrenia: precision genetics or more of the same? [Conference Abstract]. Schizophrenia Bulletin 41(Suppl1), pp. S215-S215. (10.1093/schbul/sbv010)
• Green, E. K. et al. 2015. Copy number variation in bipolar disorder. Molecular Psychiatry 21(1), pp. 89-93. (10.1038/mp.2014.174)
• Rees, E. et al. 2015. Analysis of exome sequence in 604 trios for recessive genotypes in schizophrenia. Translational Psychiatry 5(7), article number: e607. (10.1038/tp.2015.99)

2014

• Gusev, A. et al. 2014. Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. American Journal of Human Genetics 95(5), pp. 535-552. (10.1016/j.ajhg.2014.10.004)
• Timpson, N. J. et al. 2014. A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. Nature Communications 5, article number: 4871. (10.1038/ncomms5871)
• Szatkiewicz, J. P. et al. 2014. Copy number variation in schizophrenia in Sweden. Molecular Psychiatry 19(7), pp. 762-773. (10.1038/mp.2014.40)
• Ripke, S. et al. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510), pp. 421-427. (10.1038/nature13595)
• Rees, E., Walters, J. T. R., Owen, M. J. and Kirov, G. 2014. Authors' reply [Letter]. British Journal of Psychiatry 205(1), pp. 78. (10.1192/bjp.205.1.78)
• Morris, D. W. et al. 2014. An inherited duplication at the gene p21 Protein-Activated Kinase 7 (PAK7) is a risk factor for psychosis. Human Molecular Genetics 23(12), pp. 3316-3326. (10.1093/hmg/ddu025)
• Rees, E. et al. 2014. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Human Molecular Genetics 23(6), pp. 1669-1676. (10.1093/hmg/ddt540)
• Monks, S. et al. 2014. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome. Schizophrenia Research 153(1-3), pp. 231-236. (10.1016/j.schres.2014.01.020)
• Rees, E. et al. 2014. Analysis of copy number variations at 15 schizophrenia-associated loci. British Journal of Psychiatry 204(2), pp. 108-114. (10.1192/bjp.bp.113.131052)

2013

• Schmechtig, A. et al. 2013. The effects of ketamine and risperidone on eye movement control in healthy volunteers. Translational Psychiatry 3(12), article number: e334. (10.1038/tp.2013.109)
• Rees, E. et al. 2013. Evidence that duplications of 22q11.2 protect against schizophrenia. Molecular Psychiatry n/a (10.1038/mp.2013.156)
• Ripke, S. et al. 2013. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics 45(10), pp. 1150-1159. (10.1038/ng.2742)
• Walters, J. T. R. et al. 2013. The role of the major histocompatibility complex region in cognition and brain structure: a schizophrenia GWAS follow-up. American Journal of Psychiatry 170(8), pp. 877-885. (10.1176/appi.ajp.2013.12020226)
• Hamshere, M. L. et al. 2013. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Molecular Psychiatry 18(6), pp. 708-712. (10.1038/mp.2012.67)
• Niarchou, M., Zammit, S., Walters, J. T. R., Lewis, G., Owen, M. J. and van den Bree, M. B. 2013. Defective processing speed and nonclinical psychotic experiences in children: longitudinal analyses in a large birth cohort. American Journal of Psychiatry 170(5), pp. 550-557. (10.1176/appi.ajp.2012.12060792)
• Donohoe, G. et al. 2013. Neuropsychological effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10503253. Genes, Brain and Behavior 12(2), pp. 203-209. (10.1111/gbb.12016)
• Kirov, G. et al. 2013. The penetrance of copy number variations for schizophrenia and developmental delay. Biological Psychiatry 75(5), pp. 378-385. (10.1016/j.biopsych.2013.07.022)

2012

• O'Donovan, M. C., Owen, M. J., Walters, J. T. R., Irish Schizophrenia Genomics Consortium, . and Wellcome Trust Case Control Consortium 2, . 2012. Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biological psychiatry 72(8), pp. 620-628. (10.1016/j.biopsych.2012.05.035)
• Koychev, I. et al. 2012. A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study. European Neuropsychopharmacology 22(7), pp. 469-481. (10.1016/j.euroneuro.2011.10.005)
• Economou, A. et al. 2012. The health informatics cohort enhancement project (HICE): using routinely collected primary care data to identify people with a lifetime diagnosis of psychotic disorder. BMC Research Notes 5(1), pp. 95-100. (10.1186/1756-0500-5-95)

2011

• Altınbaş, K., Altınbaş, G., Türkcan, A., Oral, E. T. and Walters, J. T. R. 2011. A survey of verbal and physical assaults towards psychiatrists in Turkey. International Journal of Social Psychiatry 57(6), pp. 631-636. (10.1177/0020764010382364)
• Stergiakouli, E. et al. 2011. Steroid sulfatase is a potential modifier of cognition in attention deficit hyperactivity disorder. Genes Brain and Behavior 10(3), pp. 334-344. (10.1111/j.1601-183x.2010.00672.x)
• Carroll, L. S., Williams, H. J., Walters, J. T. R., Kirov, G., O'Donovan, M. C. and Owen, M. J. 2011. Mutation screening of the 3q29 microdeletion syndrome candidate genes DLG1 and PAK2 in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 156(7), pp. 844-849. (10.1002/ajmg.b.31231)
• Donohoe, G. et al. 2011. A neuropsychological investigation of the genome wide associated schizophrenia risk variant NRGN rs12807809 [Letter]. Schizophrenia Research 125(2-3), pp. 304-306. (10.1016/j.schres.2010.10.019)
• Dwyer, S. L. et al. 2011. Investigation of rare non-synonymous variants at ABCA13 in schizophrenia and bipolar disorder [letter]. Molecular Psychiatry 16(8), pp. 790-791. (10.1038/mp.2011.2)

2010

• Walters, J. T. R. et al. 2010. Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Archives of General Psychiatry 67(7), pp. 692-700. (10.1001/archgenpsychiatry.2010.81)

2009

• Donohoe, G. et al. 2009. Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. Archives of General Psychiatry 66(10), pp. 1045-1054. (10.1001/archgenpsychiatry.2009.139)
• Smith, D. J. et al. 2009. Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. Acta Psychiatrica Scandinavica 119(4), pp. 325-329. (10.1111/j.1600-0447.2008.01324.x)

2008

• Craddock, N. J. et al. 2008. Wake up call: Response from authors [eLetter]. British Journal of Psychiatry
• Walters, J. T. R. and Jones, I. R. 2008. Clinical questions and uncertainty - prolactin measurement in patients with schizophrenia and bipolar disorder. Journal of Psychopharmacology 22(Supp 2), pp. 82-89. (10.1177/0269881107086516)
• Robertson Blackmore, E., Craddock, N. J., Walters, J. T. R. and Jones, I. R. 2008. Is the perimenopause a time of increased risk of recurrence in women with a history of bipolar affective postpartum psychosis? A case series. Archives of Women's Mental Health 11(1), pp. 75-78. (10.1007/s00737-008-0215-2)
• Smith, D. J. et al. 2008. Differences in depressive symptom profile between males and females. Journal of Affective Disorders 108(3), pp. 279-284. (10.1016/j.jad.2007.10.001)
• Craddock, N. J. et al. 2008. Authors' reply. The British Journal of Psychiatry 193(6), pp. 517. (10.1192/bjp.193.6.517)
• Craddock, N. J. et al. 2008. Wake-up call for British psychiatry. British Journal of Psychiatry 193(1), pp. 6-9. (10.1192/bjp.bp.108.053561)

2007

• Walters, J. T. R. and Owen, M. J. 2007. Endophenotypes in psychiatric genetics [Guest Editorial]. Molecular Psychiatry 12(10), pp. 886-890. (10.1038/sj.mp.4002068)
• Smith, D. J. and Walters, J. T. R. 2007. Bipolarity is important during treatment with antidepressants [Comment]. British Medical Journal (BMJ) 334(7589), pp. 327-327. (10.1136/bmj.39121.846667.1F)
• Walters, J. T. R., Bisson, J. I. and Shepherd, J. P. 2007. Predicting post-traumatic stress disorder: validation of the Trauma Screening Questionnaire in victims of assault. Psychological medicine 37(1), pp. 143-150. (10.1017/S0033291706008658)

2004

• Ohlsen, R. I., O'Toole, M. S., Purvis, R. G., Walters, J. T. R., Taylor, T. M., Jones, H. M. and Pilowsky, L. S. 2004. Clinical effectiveness in first-episode patients. European Neuropsychopharmacology 14(4), pp. S445-S451.
• O'Toole, M. S., Ohlsen, R. I., Taylor, T. M., Purvis, R., Walters, J. T. R. and Pilowsky, L. S. 2004. Treating first episode psychosis - the service users' perspective: a focus group evaluation. Journal of Psychiatric and Mental Health Nursing 11(3), pp. 319-326. (10.1111/j.1365-2850.2004.00730.x)

2003

• Taylor, T., O'Toole, M., Ohlsen, R., Walters, J. T. R. and Pilowsky, L. 2003. Safety of Quetiapine During Pregnancy. American Journal of Psychiatry 160(3), pp. 588-589. (10.1176/appi.ajp.160.3.588-a)

1996

• Toh, S. K. C., Walters, J. T. R. and Johnson, C. D. 1996. APACHE-O - A new predictor of severity in acute pancreatitis.. Gastroenterology 110(4), pp. A437-A437.